Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis.
AUTOR(ES)
Kasama, T
RESUMO
In the enclosed study we have examined the expression and contribution of specific chemokines, macrophage inflammatory protein 1 alpha (MIP-1 alpha) and macrophage inflammatory protein 2 (MIP-2), and interleukin 10 (IL-10) during the evolution of type II collagen-induced arthritis (CIA). Detectable levels of chemotactic cytokine protein for MIP-1 alpha and MIP-2 were first observed between days 32 and 36, after initial type II collagen challenge, while increases in IL-10 were found between days 36 and 44. CIA mice passively immunized with antibodies directed against either MIP-1 alpha or MIP-2 demonstrated a delay in the onset of arthritis and a reduction of the severity of arthritis. On the contrary, CIA mice receiving neutralizing anti-IL-10 antibodies demonstrated an acceleration of the onset and an increase in the severity of arthritis. Interestingly, anti-IL-10 treatment increased the expression of MIP-1 alpha and MIP-2, as well as increased myeloperoxidase (MPO) activity and leukocyte infiltration in the inflamed joints. These data suggest that MIP-1 alpha and MIP-2 play a crucial role in the initiation and maintenance, while IL-10 appears to play a regulatory role during the development of experimental arthritis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=295974Documentos Relacionados
- Restricted expression of anti-type II collagen antibody isotypes in mice suppressed for collagen-induced arthritis.
- Native type II collagen-induced arthritis in the rat. III. Relationship between the cellular immune response to native type II collagen and arthritis.
- Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
- Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis
- Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.